

A Comparative Analysis of Breast and Colon/Rectum Cancer Screening Pre-Pandemic and During the Pandemic

## DISCLOSURES



 I have no financial obligations or other conflicts of interest to disclose.

### **BACKGROUND**



#### COVID-19 ONSET IN HI

- Statewide shutdown order
- Cessation of elective procedures

### CAUTIOUS REOPENING

- Low- risk facilities and businesses reopen
- Elective procedures slowly resume

### VACCINES PHASE 1

- Phase 1a: HCP and long-term care residents
- Phase 1b: frontline workers, adults
- >=75
- Phase 1c: adults >65, high risk population

### VACCINES PHASE 2

- General public adults >= 16

MARCH 2020

MAY 2020

DECEMBER 2020

APRIL 2021

### **BACKGROUND**



- Significant decrease in STEMI PCIs, longer treatment times at centers in NY
- Significant decrease in stroke code activations and statistically significant increase in severity of stroke symptoms in LAC

- Models predict a 2% increase in cumulative breast cancer mortality due to a 12 month screening delay
- Models predict a 7.6% increase in colorectal tumor control risk and 24.7% increase in distal metastases due to a 6 month screening delay

### METHODS



 IRB approved observational, single-center retrospective study conducted at QMC

- Patients who underwent colon/rectal cancer and breast cancer screening from January 1, 2019 to June 30, 2021
  - Pre-pandemic: January 1, 2019 to February 1, 2020
  - o Pandemic: March 1, 2020 to December 31, 2020
  - o Pandemic-Vaccine Availability: January 1, 2021 to June 30, 2021

 Data obtained from the Oncology Data Registry and electronic medical records

### METHODS: DATA FIELDS



- Name
- Medical Record Number
- Zip Code
- Age
- Gender/Sex
- Race/Ethnicity
- AJCC Stage
- Tumor Histology
- Date of Cancer Diagnosis

- Date of first contact at medical center for cancer care
- Cancer treatment date
- Cancer status
- Vital status
- Date of last contact
- Insurance status
- Average household income
- Average educational level


## METHODS



Descriptive statistics applied to evaluate demographic data

- Entire QMC patient population for the three periods were evaluated
  - Observations were therefore not a sample
  - Statistical testing was not applied







### • Demographics:

- For breast and colon cancer there were no differences in age at diagnosis and race
- No differences in gender for colon cancer
- Compared throughout all three periods of evaluation



#### **Number of Patients Diagnosed by Time Period**

|                   | Total Number of Patients<br>Diagnosed | Breast Cancer<br>(N) | Breast Cancer (%) | Colorectal Cancer (N) | Colorectal Cancer<br>(%) |
|-------------------|---------------------------------------|----------------------|-------------------|-----------------------|--------------------------|
| Pre-Pandemic      | 700                                   | 459                  | 48.6%             | 241                   | 49.2%                    |
| Pandemic          | 427                                   | 286                  | 30.3%             | 141                   | 28.8%                    |
| Vaccine Available | 307                                   | 199                  | 21.1%             | 108                   | 22.0%                    |



#### Pre-Pandemic and Vaccine Available: January through June of Each Period (i.e. similar 6 month periods)

|  | Total Number of Patients<br>Diagnosed | Breast Cancer<br>(N) | Breast Cancer (%) | Colorectal Cancer (N) | Colorectal Cancer (%) |
|--|---------------------------------------|----------------------|-------------------|-----------------------|-----------------------|
| Pre-Pandemic<br>(Jan 2019 - Jun 2019)      | 289                                   | 195                  | 49.5%             | 94                    | 46.5%                 |
| Vaccine Available<br>(Jan 2021 - Jun 2021) | 307                                   | 199                  | 50.5%             | 108                   | 53.5%                 |

|                   | Proportion Diagnosed<br>Pre-Pandemic<br>Jan-Jun 2019 | 95% Confidence<br>Interval |
|-------------------|--|----------------------------|
| Breast Cancer     | 0.49   | (0.46 - 0.54)              |
| Colorectal Cancer | 0.47   | (0.40 - 0.53)              |



#### **Number of Diagnosis By Stage and Period**

#### **Breast Cancer**

|         | Pre-Pandemic<br>N (%) | Pandemic<br>N (%) | Vaccine Available<br>N (%) |
|---------|-----------------------|-------------------|----------------------------|
| Stage 0 | 59 (14.8%)            | 51 (19.7%)        | 35 (17.6%)                 |
| Stage 1 | 192 (48.2%)           | 102 (39.4%)       | 111 (55.8%)                |
| Stage 2 | 19 (4.8%)             | 11 (4.2%)         | 22 (11.1%)                 |
| Stage 3 | 3 (.8%)               | 10 (3.9%)         | 5 (2.5%)                   |
| Stage 4 | 7 (1.8%)              | 3 (1.2%)          | 8 (4.%)                    |
| Unknown | 118 (29.6%)           | 82 (31.7%)        | 18 (9.%)                   |



### **Colorectal Cancer**

| _       | Pre-Pandemic<br>N (%) | Pandemic<br>N (%) | Vaccine Available<br>N (%) |
|---------|-----------------------|-------------------|----------------------------|
| Stage 0 | 3 (1.3%)              | 1 (.7%)           | 1 (.9%)                    |
| Stage 1 | 35 (15.%)             | 15 (11.1%)        | 11 (10.2%)                 |
| Stage 2 | 52 (22.2%)            | 32 (23.7%)        | 23 (21.3%)                 |
| Stage 3 | 55 (23.5%)            | 23 (17.%)         | 30 (27.8%)                 |
| Stage 4 | 20 (8.5%)             | 24 (17.8%)        | 17 (15.7%)                 |
| Unknown | 69 (29.5%)            | 40 (29.6%)        | 26 (24.1%)                 |



# Stage 0,1 vs Stage 2-4 January-June of Vaccine Available Period compared to January-June of Pre-Pandemic

### Breast Cancer Colorectal Cancer

|           | Pre-Pandemic<br>N (%) | Vaccine Available<br>N (%) | _         | Pre-Pandemic<br>N (%) | Vaccine Available<br>N (%) |
|-----------|-----------------------|----------------------------|-----------|-----------------------|----------------------------|
| Stage 0,1 | 122 (69.7%)           | 146 (73.4%)                | Stage 0,1 | 15 (16.3%)            | 12 (11.1%)                 |
| Stage 2-4 | 12 (6.9%)             | 35 (17.6%)                 | Stage 2-4 | 50 (54.4%)            | 70 (64.8%)                 |
| Unknown   | 41 (23.4%)            | 18 (9.1%)                  | Unknown   | 27 (29.4%)            | 26 (24.1%)                 |



#### Time in Days between Screen and Treatment

#### **Breast Cancer**

|                     |                   | N   | Mean  | Std Dev | Minimum | Maximum | Lower<br>Quartile | Median | Upper<br>Quartile | IQR<br>(Inter Quartile Range) |
|---------------------|-------------------|-----|-------|---------|---------|---------|-------------------|--------|-------------------|-------------------------------|
|                     | Pre-Pandemic      | 132 | 37.5  | 54.4    | 1       | 388     | 12                | 21     | 40.5              | 12 - 40.5                     |
| Diagnosis<br>Period | Pandemic          | 92  | 129.3 | 171     | 1       | 631     | 14                | 28     | 267.5             | 14 - 268                      |
|                     | Vaccine Available | 58  | 122.1 | 197.3   | 7       | 848     | 20                | 39.5   | 80                | 20 - 80                       |

#### **Colorectal Cancer**

|  |                     |                   | N      | Mean    | Std Dev | Minimum       | Maximum  | Lower     | er<br>Median | Upper                  | IQR     |
|--|---------------------|-------------------|--------|---------|---------|---------------|----------|-----------|--------------|------------------------|---------|
|  |                     | IN                | iviean | Stu Dev | William | IVIAXIIIIUIII | Quartile | ivieulali | Quartile     | (Inter Quartile Range) |         |
|  |                     | Pre-Pandemic      | 26     | 40.1    | 38.7    | 3             | 148      | 7         | 23           | 69                     | 7 - 69  |
|  | Diagnosis<br>Period | Pandemic          | 14     | 81.4    | 132.2   | 3             | 512      | 10        | 34           | 83                     | 10 - 83 |
|  | l                   | Vaccine Available | 13     | 70.7    | 87.2    | 15            | 341      | 27        | 35           | 79                     | 27 - 79 |

### DISCUSSION



- The onset of the pandemic negatively affected screening for both breast and colorectal cancer.
- Delayed screening appears to have translated into more advanced stages of cancer at the time of diagnosis
- System factors that affected screening may have affected time to treatment

- Limitations:
  - Retrospective analysis that was obtained through administrative databases
  - Unknown stages
  - Lag time associated with data entry into Oncology Data Registry
  - o Causality cannot be determined

## FUTURE RESEARCH



- Obtain additional data through and beyond 2022 to determine if trends in late stage diagnosis and delayed treatment continue
- Compare QMC data to National Cancer Database once updated with 2021 cases

## **ACKNOWLEDGEMENTS**



I would like to extend a huge thank you to the following:

- Danny Takanishi, Jr., MD., FACS, FSSO, Mentor
- Richard Severino, MS, Biostatistician
- Sharon Blevins, CTR, Coordinator, Oncology Data Registry
- Lori Tsue, QMC Summer Research Internship Coordinator
- Kim Spencer, DNHH Summer Research Internship Coordinator
- The Queen's Medical Center Summer Research Internship Program

## SUPPLEMENTARY



## Additional Demographic Data



### Race of Patients Diagnosed with Breast Cancer

| Race   | Pre-<br>pandemic | Pre-<br>pandemic | Pandemic | Pandemic | Pandemic –<br>Vaccine<br>Available | Pandemic –<br>Vaccine<br>Available |
|--|------------------|------------------|----------|----------|------------------------------------|------------------------------------|
|  | n                | %                | n        | %        | n                                  | %                                  |
| American Indian or<br>Alaska Native          | 3                | 75.0%            | 1        | 25.0%    | 0                                  | 0.0%                               |
| Asian  | 265              | 48.5%            | 170      | 31.1%    | 112                                | 20.5%                              |
| Black or African<br>American                 | 6                | 60/0%            | 4        | 40.0%    | 0                                  | 0.0%                               |
| Native Hawaiian or<br>Other Pacific Islander | 114              | 48.3%            | 67       | 28.4%    | 55                                 | 23.3%                              |
| White  | 70               | 48.6%            | 43       | 29.9%    | 31                                 | 21.5%                              |
| Not Reported                                 | 1                | 33.3%            | 1        | 33.3%    | 1                                  | 33.3%                              |
| Total  | 459              |                  | 286      |          | 199                                |                                    |



### Race of Patients Diagnosed with Colorectal Cancer

| Race   | Pre-<br>pandemic | Pandemic |     | Pandemic | Pandemic –<br>Vaccine<br>Available | Pandemic –<br>Vaccine<br>Available |
|--|------------------|----------|-----|----------|------------------------------------|------------------------------------|
|  | n                | %        | n   | %        | n                                  | %                                  |
| American Indian or<br>Alaska Native          | 0                | 0.0%     | 0   | 0.0%     | 1                                  | 100.0%                             |
| Asian  | 139              | 50.7%    | 81  | 29.6%    | 54                                 | 19.7%                              |
| Black or African<br>American                 | 4                | 80.0%    | 0   | 0.0%     | 1                                  | 20.0%                              |
| Native Hawaiian or<br>Other Pacific Islander | 46               | 43.4%    | 33  | 23.4%    | 27                                 | 25.5%                              |
| White  | 52               | 50.5%    | 26  | 25.2%    | 25                                 | 24.3%                              |
| Not Reported                                 | 0                | 0.0%     | 1   | 100.0%   | 0                                  | 0.0%                               |
| Total  | 241              |          | 141 |          | 108                                |                                    |



### Age at Time of Diagnosis for Breast Cancer

| Time Period                   | n   | Mean | SD   | Minimum | Maximum | Lower<br>Quartile | Median | Upper<br>Quartile | IQR     |
|-------------------------------|-----|------|------|---------|---------|-------------------|--------|-------------------|---------|
| Pre-Pandemic                  | 459 | 62.4 | 13.0 | 29.0    | >89     | 53.0              | 63.0   | 71.0              | 53 - 63 |
| Pandemic                      | 286 | 61.2 | 13.7 | 28.0    | >89     | 51.0              | 62.5   | 71.0              | 51 - 71 |
| Pandemic-Vaccine<br>Available | 199 | 62.7 | 14.2 | 27.0    | >89     | 54.0              | 64.0   | 72.0              | 54 - 72 |



### Age at Time of Diagnosis for Colorectal Cancer

| Time Period                   | n   | Mean | SD   | Minimum | Maximum | Lower<br>Quartile | Median | Upper<br>Quartile | IQR     |
|-------------------------------|-----|------|------|---------|---------|-------------------|--------|-------------------|---------|
| Pre-Pandemic                  | 241 | 65.5 | 13.3 | 19.0    | > 89    | 57.0              | 64.0   | 74.0              | 57 - 74 |
| Pandemic                      | 141 | 63.6 | 13.9 | 22.0    | > 89    | 54.0              | 64.0   | 73.0              | 54 - 73 |
| Pandemic-Vaccine<br>Available | 108 | 62.6 | 14.0 | 19.0    | > 89    | 53.5              | 62.5   | 72.5              | 53 - 73 |



# Gender of Patients Diagnosed with Colorectal Cancer

| Time Period                        | Total Number of<br>Patients | Female (n) | Female (%) | Male (n) | Male (%) |
|------------------------------------|-----------------------------|------------|------------|----------|----------|
| Pre-pandemic                       | 241                         | 110        | 45.6%      | 131      | 54.4%    |
| Pandemic                           | 141                         | 69         | 48.9%      | 72       | 51.1%    |
| Pandemic –<br>Vaccine<br>Available | 108                         | 45         | 41.7%      | 63       | 58.3%    |